Bruce M. Psaty, MD, PhD

“Heart disease is the leading cause of death in the U.S., so I'm studying how genes, medications, and everyday behaviors influence heart health.”

Bruce M. Psaty, MD, PhD

Group Health Research Institute Senior Investigator

Areas of focus:

Biography

Bruce Psaty is a general internist and cardiovascular disease epidemiologist with interests and expertise in pharmaco-epidemiology, pharmacogenetics, and drug safety. Also a professor of medicine, epidemiology, and health services at the University of Washington (UW), he co-directs the UW’s Cardiovascular Health Research Unit.

Dr. Psaty’s work includes population-based case-control studies of myocardial infarction, stroke, atrial fibrillation, and venous thromboembolism conducted at Group Health Cooperative. His primary research interests include risk factors such as high blood pressure, dyslipidemia, and diabetes and the drugs used to treat these conditions; new or emerging risk factors for heart disease and stroke; genetics, genomics, and pharmacogenetics; and genetic risk factors for a variety of conditions.

His several current NIH-funded projects focus on interactions between medications and genes; they represent efforts to translate findings from the Human Genome Project into clinical practice and, thus, improve the safety and efficacy of commonly used medications. He is a founding member of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (CHARGE), which conducts genome-wide association studies in collaborating cohorts, including the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis, funded by the National Heart, Lung, and Blood Institute. He also teaches and mentors students, fellows, and junior faculty in medicine and epidemiology.

A national leader in encouraging better postmarket surveillance of approved medications, Dr. Psaty is a member of the U.S. Food and Drug Administration (FDA)’s Science Board, a committee that advises the commisioner and chief scientist. He previously served on two Institute of Medicine (IOM) panels charged with reviewing the FDA, most recently the ethical and scientific issues in studying the safety of approved drugs. Dr. Psaty is also a member of the National Heart, Lung, and Blood Institute’s Advisory Council. In 2013, he was elected to the IOM and designated a distinguished scientist by the American Heart Association.

Dr. Psaty maintains a small but long-standing primary care practice in the Adult Medicine Clinic at Harborview Medical Center.

Research interests and experience

  • Cardiovascular Health

    Myocardial infarction and stroke; venous thrombosis; atrial fibrillation; and risk factors, including hypertension, dyslipidemia, and diabetes

  • Medication Use & Patient Safety

    Pharmaco-epidemiology; drug safety

  • Genetics, Genomics, and Pharmacogenetics

  • Epidemiologic Methods

     

Recent publications

Thacker EL, Jensen PN, Psaty BM, McKnight B, Longstreth WT, Dublin S, Sitlani CM, Newton KM, Smith NL, Siscovick DS, Heckbert SR.

Use of statins and antihypertensive medications in relation to risk of longstanding persistent atrial fibrillation.

Ann Pharmacother. 2015 Jan 27. [Epub ahead of print].

Holliday EG, Traylor M, Malik R, Bevan S, Falcone G, Hopewell JC, Cheng YC, Cotlarciuc I, Bis JC, Boerwinkle E, Boncoraglio GB, Clarke R, Cole JW, Fornage M, Furie KL, Ikram MA, Jannes J, Kittner SJ, Lincz LF, Maguire JM, Meschia JF, Mosley TH, Nalls MA, Oldmeadow C, Parati EA, Psaty BM, Rothwell PM, Seshadri S, Scott RJ, Sharma P, Sudlow C, Wiggins KL, Worrall BB, Rosand J, Mitchell BD, Dichgans M, Markus HS, Levi C, Attia J, Wray NR; on behalf of the Australian Stroke Genetics Collaborative, the Wellcome Trust Case Control Consortium 2, and the International Stroke Genetics Consortium.

Genetic overlap between diagnostic subtypes of ischemic stroke.

Stroke. 2015 Jan 22. pii: STROKEAHA.114.007930. [Epub ahead of print].

Yu B, Li AH, Muzny D, Veeraraghavan N, de Vries PS, Bis JC, Musani SK, Alexander D, Morrison AC, Franco OH, Uitterlinden A, Hofman A, Dehghan A, Wilson JG, Psaty BM, Gibbs R, Wei P, Boerwinkle E.

Association of rare loss-of-function alleles in HAL, serum histidine levels and incident coronary heart disease.

Circ Cardiovasc Genet. 2015 Jan 8. pii: CIRCGENETICS.114.000697. [Epub ahead of print].

Dashti HS, Follis JL, Smith CE, Tanaka T, Cade BE, Gottlieb DJ, Hruby A, Jacques PF, Lamon-Fava S, Richardson K, Saxena R, Scheer FA, Kovanen L, Bartz TM, Perälä MM, Jonsson A, Frazier-Wood AC, Kalafati IP, Mikkilä V, Partonen T, Lemaitre RN, Lahti J, Hernandez DG, Toft U, Johnson WC, Kanoni S, Raitakari OT, Perola M, Psaty BM, Ferrucci L, Grarup N, Highland HM, Rallidis L, Kähönen M, Havulinna AS, Siscovick DS, Räikkönen K, Jørgensen T, Rotter JI, Deloukas P, Viikari JS, Mozaffarian D, Linneberg A, Seppälä I, Hansen T, Salomaa V, Gharib SA, Eriksson JG, Bandinelli S, Pedersen O, Rich SS, Dedoussis G, Lehtimäki T, Ordovás JM.

Habitual sleep duration is associated with BMI and macronutrient intake and may be modified by CLOCK genetic variants.

Am J Clin Nutr. 2015;101(1):135-43. doi: 10.3945/ajcn.114.095026. Epub 2014 Nov 26. PubMed